Resources
Psychedelic Research Resources
MAPS
Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.
Zendo Project
This year, millions of people will use psychedelics outside of supervised medical contexts, many of them for the first time. Taking psychedelics can result in overwhelming and uncomfortable experiences, more likely with high doses, amongst first-time users, and without adequate preparation or setting. The Zendo Project promotoes psychedelic harm reductio, including a variety of methods to help prevent and transform difficult experiences while in a non-ordinary state of consciousness.
The Center for Psychedelic Therapy Research
Located at Mount Sinai and the James J. Peters Department of Veterans Affairs Medical Center, The Center for Psychedelic Therapy Research examines the therapeutic potential of psychedelic compounds for post-traumatic stress disorder (PTSD) and other trauma-related symptoms.
Participate in Research
ClinicalTrials.gov
ClinicalTrials.gov hosts a large collection of clinical studies from around the world. You can search for studies using keywords such as a condition or disease, drug, or medical device. To help focus your search, you can use more than one keyword.
Recent Publications
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Clinical research with psychedelics has provided promising positive results for various mental disorders (Andersen et al., 2020; Bahji et al., 2020; Dos Santos et al., 2018; Vargas et al., 2020). However, sample sizes...
How Do Researchers Measure a Psychedelic Trip? The Power of 5D-ASC
The acronym 5D-ASC refers to Five-Dimensional Altered States of Consciousness. This framework offers researchers a powerful tool for analyzing and quantifying subjective experiences encountered during psychedelic journeys. Through careful development and empirical testing, 5D-ASC has emerged.
FDA Grants Accelerated Approval for as a Breakthrough Treatment for Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) granted accelerated approval for Leqembi (lecanemab-irmb) as a groundbreaking treatment. This marks a pivotal moment in the ongoing battle against Alzheimer's, with Leqembi being the second medication approved for the disease designed to tackle its fundamental pathophysiology.